Parabilis Medicines

Desmoid tumour
#Financing #Oncology #Parabilis Medicines

Parabilis Medicines announces oversubscribed $305m financing

Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing.  The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment… Read More

#Business & Investment #Cancer Research #News

#Cancer research #Parabilis Medicines #Prostate cancer #Toxicology

Cracking the ERG code in prostate cancer

Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this?   JH: ERG… Read More

#Cancer Research #Exclusive Content